Elevated plasma hyaluronan levels in pulmonary hypertension

Tohoku Journal of Experimental Medicine

Volumn 230, Issue 1, 2013, Pages 7-11

  Kalay, Nihat ^a   Elcik, Deniz ^a   Canatan, Halit ^a   Kaya, Mehmet Gungor ^a   Yarlioglues, Mikail ^a   Oguzhan, Abdurrahman ^a   Dweik, Raed A ^b   Aytekin, Metin ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Extracellular matrix; Heart failure; Hyaluronan; Pulmonary arterial hypertension

Indexed keywords

HYALURONIC ACID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FEMALE; HEART EJECTION FRACTION; HUMAN; LUNG ARTERY PRESSURE; MALE; OPTICAL DENSITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SEX DIFFERENCE; SYSTOLIC HEART FAILURE; THROMBOCYTE VOLUME;

CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HEART FAILURE; HUMANS; HYALURONIC ACID; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84876988531     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.230.7     Document Type: Article

References (29)

1. Abdool-Gaffar, M.S., Ambaram, A., Ainslie, G.M., Bolliger, C.T., Feldman, C., Geffen, L., Irusen, E.M., Joubert, J., Lalloo, U.G., Mabaso, T.T., Nyamande, K., O'Brien, J., Otto, W., Raine, R., Richards, G., Smith, C., Stickells, D., Venter, A., Visser, S. & Wong, M. (2011) Guideline for the management of chronic obstructive pulmonary disease - 2011 update. S. Afr. Med. J., 101, 63-73.
2. Aldred, M.A., Vijayakrishnan, J., James, V., Soubrier, F., Gomez-Sanchez, M.A., Martensson, G., Galie, N., Manes, A., Corris, P., Simonneau, G., Humbert, M., Morrell, N.W. & Trembath, R.C. (2006) BMPR2 gene rearrangements account for a signifcant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum. Mutat., 27, 212-213.
3. Aytekin, M. & Caylak, E. (2009) Hyaluronan and the importance of hyaluronan in diagnosis and treatment. Tuberk. Toraks., 57, 356-364.
4. Aytekin, M., Comhair, S.A., de la Motte, C., Bandyopadhyay, S.K., Farver, C.F., Hascall, V.C., Erzurum, S.C. & Dweik, R.A. (2008) High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol., 295, L789-799.
5. Baumgartner, H., Hung, J., Bermejo, J., Chambers, J.B., Evangelista, A., Griffn, B.P., Iung, B., Otto, C.M., Pellikka, P.A. & Quinones, M. (2009) Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J. Am. Soc. Echocardiogr., 22, 1-23, quiz 101-102.
6. Borgeson, D.D., Seward, J.B., Miller, F.A., Oh, J.K. & Tajik, A.J. (1996) Frequency of Doppler measurable pulmonary artery pressures. J. Am. Soc. Echocardiogr., 9, 832-837.
7. de la Motte, C., Nigro, J., Vasanji, A., Rho, H., Kessler, S., Bandyopadhyay, S., Danese, S., Fiocchi, C. & Stern, R. (2009) Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proin-fammatory cytokines. Am. J. Pathol., 174, 2254-2264.
8. de la Motte, C.A. (2011) Hyaluronan in intestinal homeostasis and inflammation: implications for fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 301, G945-949.
9. Dentener, M.A., Vernooy, J.H., Hendriks, S. & Wouters, E.F. (2005) Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local infam-mation. Thorax, 60, 114-119.
10. Drost, E.M., Skwarski, K.M., Sauleda, J., Soler, N., Roca, J., Agusti, A. & MacNee, W. (2005) Oxidative stress and airway infammation in severe exacerbations of COPD. Thorax, 60, 293-300.
11. Evanko, S.P., Angello, J.C. & Wight, T.N. (1999) Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 19, 1004-1013.
12. Ghamra, Z.W. & Dweik, R.A. (2003) Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve. Clin. J. Med., 70 Suppl 1, S2-8.
13. Haserodt, S., Aytekin, M. & Dweik, R.A. (2011) A comparison of the sensitivity, specifcity, and molecular weight accuracy of three different commercially available Hyaluronan ELISA-like assays. Glycobiology, 21, 175-183.
14. Heresi, G.A., Tang, W.H., Aytekin, M., Hammel, J., Hazen, S.L. & Dweik, R.A. (2012) Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur. Respir. J., 39, 939-944.
15. Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M., Christman, B.W., Weir, E.K., Eickelberg, O., Voelkel, N.F. & Rabinovitch, M. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol., 43, 13S-24S.
16. Kjaergaard, J., Akkan, D., Iversen, K.K., Kjoller, E., Kober, L., Torp-Pedersen, C. & Hassager, C. (2007) Prognostic importance of pulmonary hypertension in patients with heart failure. Am. J. Cardiol., 99, 1146-1150.
17. Laurent, T.C. & Fraser, J.R. (1992) Hyaluronan. FASEB J., 6, 2397-2404.
18. McLaughlin, V. V. & McGoon, M.D. (2006) Pulmonary arterial hypertension. Circulation, 114, 1417-1431.
19. Moraes, D.L., Colucci, W.S. & Givertz, M.M. (2000) Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation, 102, 1718-1723.
20. Papakonstantinou, E., Kouri, F.M., Karakiulakis, G., Klagas, I. & Eickelberg, O. (2008) Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur. Respir. J., 32, 1504-1512.
21. Pietra, G.G., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I.M., Reid, L.M. & Tuder, R.M. (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J. Am. Coll. Cardiol., 43, 25S-32S.
22. Stewart, S. & Rassl, D. (2009) Advances in the understanding and classifcation of pulmonary hypertension. Histopathology, 54, 104-116.
23. Szwejkowski, B.R., Elder, D.H., Shearer, F., Jack, D., Choy, A.M., Pringle, S.D., Struthers, A.D., George, J. & Lang, C.C. (2012) Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur. J. Heart Fail., 14, 162-167.
24. Teder, P., Vandivier, R.W., Jiang, D., Liang, J., Cohn, L., Pure, E., Henson, P.M. & Noble, P.W. (2002) Resolution of lung infammation by CD44. Science, 296, 155-158.
25. Teichholz, L.E., Kreulen, T., Herman, M.V. & Gorlin, R. (1976) Problems in echocardiographic volume determinations: echo-cardiographic-angiographic correlations in the presence of absence of asynergy. Am. J. Cardiol., 37, 7-11.
26. Thabut, G., Dauriat, G., Stern, J.B., Logeart, D., Levy, A., Marrash-Chahla, R. & Mal, H. (2005) Pulmonary hemody-namics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest, 127, 1531-1536.
27. White, M., Ducharme, A., Ibrahim, R., Whittom, L., Lavoie, J., Guertin, M.C., Racine, N., He, Y., Yao, G., Rouleau, J.L., Schiffrin, E.L. & Touyz, R.M. (2006) Increased systemic infammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin. Sci. (Lond.), 110, 483-489.
28. Wright, J.L., Levy, R.D. & Churg, A. (2005) Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax, 60, 605-609.
29. Xu, Q., Dalic, A., Fang, L., Kiriazis, H., Ritchie, R.H., Sim, K., Gao, X.M., Drummond, G., Sarwar, M., Zhang, Y.Y., Dart, A.M. & Du, X.J. (2011) Myocardial oxidative stress contributes to transgenic beta-adrenoceptor activation-induced cardiomyopathy and heart failure. Br. J. Pharmacol., 162, 1012-1028.